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Purpose: The purpose of this study was to describe our experience with endoluminal graft repair of a variety of thoracic
aorta pathologies with a commercially developed device currently under investigation. Our patient population included
patients eligible for open surgical repair and those with prohibitive surgical risk.
Methods: From February 2000 to February 2001, endovascular stent-graft repair of the thoracic aorta was performed in
46 patients (mean age, 70 years; 29 male and 17 female patients) with the Gore Excluder. Twenty-three patients (50%)
had atherosclerotic aneurysms, 14 patients (30%) had dissections, three patients (7%) had aortobronchial fistulas, three
patients (7%) had pseudoaneurysms, two patients (4%) had traumatic ruptures, and one patient (2%) had a ruptured aortic
ulcer. Patient characteristics, procedural variables, outcome, and complications were recorded. All patients were followed
with chest computed tomographic scans at 1, 3, 6, and 12 months. Follow-up period ranged from 1 month to 15 months,
with a mean of 8.5 months.
Results: All the procedures were technically successful. There were no conversions. Average duration of the procedure was
120 minutes. Average length of stay was 6 days, but most patients (64%) left the hospital within 4 days after endoluminal
grafting. The overall morbidity rate was 23%. Two patients (4%) had endoleaks that necessitated a second procedure for
successful repair. Two patients (4%) died in the immediate postoperative period. There were no cases of paraplegia. At
follow-up examination, one patient had an endoleak found the day after the procedure and another patient had an
endoleak 6 months after the procedure. Both cases were treated successfully with additional stent-grafts. There were no
cases of migration. One patient died of a myocardial infarction 6 months after graft placement. In patients treated for
aneurysm (n  23), the aneurysm diameter ranged from 5.0 to 9.5 cm (mean, 6.8 cm). Residual sac measurements were
obtained at 1, 6, and 12 months, with mean sac reductions of 0.59 cm, 0.77 cm, and 0.85 cm, respectively. In three cases,
the sac remained unchanged, without evidence of endoleak.
Conclusion: Thoracic endoluminal grafting with the Gore Excluder is a safe and feasible alternative to open graft repair
and can be performed successfully with good results. Early data suggest an endoluminal approach to these disease entities
may be favorable over classical resection and graft replacement. (J Vasc Surg 2002;35:1163-70.)
Thoracic aortic dissections, ruptures, fistulas, and an-
eurysms pose a unique surgical challenge. Traditional repair
of thoracic aortic aneurysms involves thoracotomy with
graft interposition. Despite advances in perioperative care
and both total and partial cardiopulmonary bypass proce-
dures, conventional surgery still carries a significant mor-
bidity and mortality risk. Principal complications include
bleeding, paraplegia, stroke, cardiac events, pulmonary in-
sufficiency, and renal failure.1-5 Recent enthusiasm for in-
novative endovascular therapies in the treatment of aortic
disease has spurred many centers to investigate endolumi-
nal grafting of the thoracic aorta. Early reports on endovas-
cular repair with custom-made “first-generation devices”
showed the technique to be feasible with a mortality and
morbidity rate comparable with that of open repair.6-11
In February 2000, we initiated a single-center research
protocol on the basis of an investigational device exception
with a “second-generation” device. Improvement in the
device design reflected in the Gore Excluder thoracic stent-
graft (WL Gore, Flagstaff, Ariz) has allowed us to pursue
complex thoracic surgical problems with endovascular ap-
proaches. Although previous studies of thoracic stent-grafts
have only reported the use in patients at high risk, our
population included those patients who would have other-
wise been surgical candidates. We report our initial experi-
ence with this thoracic aortic endoluminal graft in the
treatment of a variety diseases of the thoracic aorta.
METHODS
During 2000, 46 patients were admitted to the Arizona
Heart Hospital for thoracic endoluminal grafting to treat
thoracic aortic aneurysms, pseudoaneurysms, dissections,
aortobronchial fistulas, acute traumatic ruptures, and aortic
ulcers. All prospective patients were enrolled with the pro-
visions of a Food and Drug Administration Investigational
Devices Exemption for the Gore Excluder without excep-
tions during this period of time. The thoracic Gore Ex-
cluder protocol in our institution was in compliance with
the Institutional Review Board of the Arizona Heart Hos-
pital.
The Gore Excluder is a self-expandable endoprothesis
of an expanded polytetrafluoroethylene tube and an exter-
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nal nitinol wire support structure designed for the thoracic
aorta (Fig 1). The graft is mounted on a flexible delivery
system and surrounded by a sleeve of expanded polytetra-
fluoroethylene (Fig 2). A pull wire releases the corset, and
deployment occurs first in the middle of the graft and then
rapidly proceeds to the proximal and distal ends (Fig 3). A
unique trilobed aortic balloon expands the graft for aortic
apposition without complete aortic occlusion (Fig 4). The
intended size specifications, graft diameters, graft length,
and sheath sizes are given in Table I.
Each patient was evaluated by a staff surgeon and
underwent chest roentgenography and contrast-enhanced
computed tomographic (CT) scanning before the proce-
dure. Angiography was performed with a calibrated cathe-
ter for the thoracic aortic component with studies of the
abdominal and iliac vessels. Patients were chosen for en-
doluminal grafting according to presenting pathology and
suitability of anatomy for device implantation. The aortic
measurements were made from the preoperative studies for
determination of device diameter and length. All stent-
grafts were oversized 2 mm to 6 mm compared with the
proximal neck diameter (Table I). Length of the device was
chosen on the basis of the length of the lesion and at least 2
cm of both proximal and distal landing zones. For graft
pseudoaneurysms and aortobronchial fistulas caused by
previous interposition graft material, a length was chosen to
transverse both anastomoses to ensure no further paraanas-
tomotic leakage.
If the lesions were in close proximity to the subclavian
artery with less than 2 cm of neck for the proximal landing
zone, a standard carotid subclavian bypass procedure or
transposition was performed before the endovascular pro-
cedure. Distal aortic arch and proximal descending thoracic
lesions therefore were treated in our series. These cases
were generally staged. However, in one instance, an un-
planned procedure was performed immediately after a de-
vice was placed over the left subclavian artery. Concern
existed not only for an ischemic process but for persistence
of retrograde flow to the aneurysmal sac. The origin of the
subclavian artery was either ligated or diverted with a
transposition to the carotid artery.
All procedures were performed with general anesthesia
in endovascular suites equipped with fluoroscopic and an-
giographic equipment. The artery for transluminal device
placement was selected on the basis of the degree of ob-
structing atherosclerotic plaque. One femoral arery was
surgically exposed for device delivery. Percutaneous access
was obtained through the contralateral common femoral
artery. Through the left brachial artery, a 4F or 5F pigtail
catheter was placed to assist in accurate identification of the
left subclavian artery.
In those patients with diseased iliac arteries, balloon
angioplasty was performed to allow passage of the delivery
system. If severe obstructing atherosclerotic plaque in the
iliac vessels prohibited femoral artery delivery, an iliac artery
delivery was performed through a retroperitoneal ap-
proach. The iliac artery was exposed through a transverse
lower abdominal incision and retroperitoneal dissection.
An end-to-side anastomosis was created between the com-
mon iliac artery and a 10-mm Hemashield graft conduit
(Boston Scientific, Natick, Mass). The device was translu-
minally placed into the aorta through this conduit. At the
completion of the procedure, this conduit was attached to
the common femoral artery, creating an iliofemoral bypass.
Arteriography, transesophageal echocardiography (TEE),
and intravascular ultrasound scanning (IVUS) were used to
determine precise aortic landing zones. Aortic diameters
also were confirmed during the procedure with IVUS. A
shelf stock of devices allowed selection of the appropriate
size on the basis of the preoperative CT scan measurements
and the intraoperative measurements. TEE and IVUS pre-
cisely located pseudoaneurysms, fistulas, entry and exit
points of dissections, and false lumens that are not easily or
accurately detected with aortography or CT scans. A Keller-
Tillerman introducer sheath (Cook, Inc, Bloomington,
Ind) was inserted through the femoral or iliac artery over a
0.035-inch “superstiff” wire (Amplatz, Meditech, Boston
Scientific, Boston, Mass; or Flex Finder, Microvena, White
Bear Lake, Mich). The delivery system was loaded onto the
wire and through the sheath to the level of the thoracic
Fig 1. Gore Excluder, self-expandable endoprothesis for thoracic
aorta. Device is made of expanded polytetrafluoroethylene inner
tube and outer nitinol exoskeleton.
Fig 2. Device loaded on flexible over-wire delivery system with
polytetrafluoroethylene sleeve. Wire is pulled for deployment.
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aorta. If the rigid sheath could not negotiate tortuous or
diseased iliac arteries, then the device was placed “bare-
back” without the sheath. Arterial control then was man-
aged with a Rummel tourniquet, and device exchange was
more complicated. Once the delivery system was in place,
arterial pressure was pharmacologically lowered to less than
100 mm Hg before deployment. The device was directed
into place with arteriography, fluoroscopy, and TEE. Rapid
graft deployment with a pull-wire system prevented signif-
icant graft migration. Completion arteriography was per-
formed to confirm adequate placement and exclusion with-
out endoleak. TEE and IVUS confirmed elimination of
pulsatile flow in the false lumen of dissections, exclusion of
fistulas, and exclusion of aneurysms.
The patients were monitored in the recovery room or
intensive care unit overnight. A CT scan was obtained
before discharge to confirm adequate placement and lack of
endoleak. All postoperative care was directed by the surgi-
cal team. Contrast CT scans were repeated at 3 months, 6
months, and 1 year, with routine evaluation for aneurysmal
sac measurements and presence of endoleak.
RESULTS
From February 2000 to February 2001, 46 patients at
the Arizona Heart Hospital underwent treatment with
thoracic stent-graft placement (Figs 5 and 6). The patients
were operative and nonoperative candidates. All patients
were of American Society of Anesthesiology classification
III or IV, on the basis of their comorbid conditions (Table
II). A total of 46 patients received 54 grafts during 48
operations for aneurysms, dissections, pseudoaneurysms,
aortobronchial fistulas, and an aortic ulcer (Table III).
Three patients (6.5%) had contained ruptures. No open
conversions were necessary (Table IV). One patient had a
significant endoleak after the procedure, which necessitated
a return to the operative suite 2 days after the initial
procedure. The leak was successfully excluded with a sec-
ond graft on the second postoperative day. A second pa-
tient had an endoleak 5 months after the original graft
placement. This also was successfully managed with an-
other device placement.
Access played an important role in facilitating the op-
eration. Iliac arteries with extensive occlusive disease re-
quired dilatation and balloon angioplasty to accommodate
device placement into the aorta. However, six patients
(13%) needed iliac access via a retroperitoneal approach
Fig 3. Graft deploys in middle first and then proceeds toward distal ends.
Fig 4. Aortic balloon has trilobed configuration for aortic appo-
sition without impedance of aortic blood flow.
Table I. Gore Thoracic Excluder sizing guide
Intended
aortic
diameter
(mm)
Endoprothesis
diameter
(mm)
Overall
endoprothesis
lengths (cm)
Recommended
sheath size
23-24 26 7.5, 10, 12.5 22F
24-26 28 7.5, 10, 12.5, 15 22F
26-29 31 7.5, 10, 12.5, 15 22F
29-32 34 10, 12.5, 15, 20 24F
32-34 37 10, 12.5, 15, 20 24F
34-37 40 10, 12.5, 15, 20 24F
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because of tortuous or diseased iliac arteries, and an iliac-
femoral bypass procedure was performed after deployment
through an iliac graft conduit. Mean operative time was
120 minutes (Table IV), and the actual surgical time de-
creased as we became familiar with the operative technique.
Mean estimated blood loss was 300 mL. Most patients
(64%) left the hospital within 4 days after the stent-grafting.
The average length of stay was 5 days, and all patients who
stayed longer had second procedures during the same
hospitalization (Table V). Seven patients needed carotid
subclavian bypass procedure or transposition before stent
placement.
Two patients died in the perioperative period, for an
early mortality rate of 4% (Table VI). One patient died after
an iliac artery rupture caused by a sheath perforation during
device deployment. The second death occurred after the
repair of a ruptured thoracic aortic aneurysm. An emer-
gency repair was performed with successful device deploy-
ment. However, the patient died 24 hours after the proce-
dure. Autopsy results found the cause of death to be diffuse
Fig 5. Preoperative angiogram (A) and CT scan (B) show 7-cm aneurysm in distal aortic arch and proximal
descending thoracic aortic in 72-year-old patient.
Fig 6. Postoperative angiogram (A) and CT scan (B) after deployment of Gore Excluder stent-graft show adequate
exclusion of aneurysm described in Fig 5. Carotid subclavian bypass procedure was performed before stent placement
to allow for adequate landing proximal landing zone.
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embolization and ischemia of the visceral organs. A third
patient died of a myocardial infarction 6 months after the
procedure.
The morbidity rate was 23%, including major and mi-
nor events (Table VI). Postoperative complications in-
cluded pulmonary complications, such as atelectasis and
pneumonia, renal insufficiency, mesenteric ischemia, local
hemorrhage, iliac conduit, and lower extremity thrombo-
sis. One patient (2%) had a left hemispheric cerebrovascular
accident after the procedure. There were no cases of para-
plegia. There were no cases of renal failure requiring dialy-
sis.
The follow-up period ranged from 1 to 15 months,
with a mean of 8.5 months. During the follow-up period,
residual sac measurements were obtained in patients who
underwent treatment for aneurysms or dissections with
aneurysmal changes. Before surgery, the size of the sac
ranged from 5.0 to 9.5 cm, with a mean of 6.8 cm. Sac
measurements were available in 16 of the 23 patients with
aneurysms (70%) (Table VII). At 1 month, the sac shrunk
from a mean of 6.86 cm to 6.27 cm, for a mean reduction
of 0.59 cm. At 6 months, 10 of 23 patients (43.4%) had sac
measurements available. In seven of 10 patients (70%), the
sac reduced from a preoperative mean of 6.74 cm to 5.97
cm, for a mean reduction of 0.77 cm. In the remaining
three cases, the sac was unchanged. No symptoms or en-
doleaks were found in those patients.
At 12 months, two patients had sac measurements.
Diameter decreased from 6.1 cm to a mean of 5.25 cm, for
a mean reduction of 0.85 cm (Table VII). All grafts re-
mained patent and properly positioned. There were no
ruptures.
DISCUSSION
Conventional surgical treatment of thoracic aortic an-
eurysms, dissections, ulcers, aortobronchial fistulas, pseudo-
aneurysms, and traumatic ruptures involves open thoracot-
omy, aortic cross clamping, extracorporeal circulation, and
Table II. Patient characteristics and comorbidities
Patient characteristic/comorbidity No.
Mean age (years; range) 70 (45-86)
Male/female ratio 29/17
Hypertension 34 (73%)
Coronary artery disease 23 (50%)
COPD 20 (44%)
AAA 14 (30%)
Previous thoracotomy 13 (28%)
Periphereal vascular disease 11 (23%)
Hyperlipidemia 9 (20%)
Congestive heart failure 6 (13%)
Renal insufficiency 6 (13%)
Diabetes mellitus 6 (13%)
Previous CVA 4 (9%)
Morbid obesity 3 (8%)
Oxygen dependence 2 (7%)
Steroid dependence 2 (7%)
Multitrauma 2 (7%)
COPD, Chronic obstructive pulmonary disease; AAA, abdominal aortic
aneurysm; CVA, cerebrovascular accident.
Table III. Anatomic characteristics
Lesion No.
Atherosclerotic aneurysm 23 (50%)
Dissection 14 (30%)
Aortobronchial fistula 3 (7%)
Pseudoaneurysm 3 (7%)
Traumatic rupture 2 (4%)
Aortic ulcer 1 (2%)
Table IV. Procedural characteristics
Variable
Operating time (minutes) 120 (60-350)
Contrast (mL) 360 (106-860)
Blood loss (mL) 292 (100-1000)
Femoral access/iliac access 40/6
Endoleaks 2
Conversions 0
Length of stay (days) 5.6
Table V. Procedures on same admission
Procedure No.
Carotid subclavian bypass or transposition 7
Abdominal aortic aneurysm repair 3
Thrombectomy of iliac conduit 1
Thrombectomy of lower extremity 1
Reexploration of hemorrhage from conduit 1
Table VI. Morbidity and mortality
Complication No. of Events
Pneumonia/atelectasis/prolonged ventilation 5 (11%)
Renal insufficiency (not needing dialysis) 2 (4%)
Groin hematoma 1 (2%)
Iliac conduit hemorrhage 1 (2%)
Iliac conduit thrombosis 1 (2%)
Lower extremity thrombosis 1 (2%)
Mesenteric ischemia 1 (2%)
Stroke 1 (2%)
Early mortality 2 (4%)
Late morality 1 (2%)
Table VII. Changes in aneurysmal sac measurements
Measurements of aneurysms
(n  23; 50%)
Follow-up interval
(mean size/mean reduction)
No.
Before surgery
(mean; cm) 1 month 6 months 12 months
16 (70%) 6.86 6.27 (0.59) — —
10 (43.4%) 6.74 — 5.97 (0.77) —
2 (8.7%) 6.10 — — 5.25 (0.85)
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graft interposition. Patients are often elderly and have
severe comorbidities, making them poor surgical candi-
dates. However, the natural history of these conditions if
untreated is progression of the disease, eventual rupture,
and usually death.12,13 Given the gravity of thoracic pathol-
ogies, repair should be undertaken in most patients. The
decision to proceed with repair must be balanced with the
consideration of the complexity of the procedure in an
elderly patient at high risk. Even with elective conditions at
specialized centers, the operative mortality rate of thoracic
aneurysms is reported between 3% and 20%.1,3,4 Acute
aortic dissections present an even greater challenge with
surgical mortality rates reported as high as 50%.14,15 Com-
plications include pulmonary insufficiency, ventilator de-
pendency, myocardial infarction, renal failure, coagulopa-
thy, and neurologic injury. Inadvertent compromise of the
origin of landing zone branches (subclavian or celiac or
both) is a potential complication. The incidence rate of
postoperative paraplegia is 4% to 14%.1-4 Patients usually
undergo a prolonged convalescence from an extensive op-
eration. Strategies that incorporate less invasive techniques
may offer a more desirable outcome and thus provide the
impetus to seek a less physiologically demanding therapy.
Recent advances in endovascular therapies have pro-
vided unique solutions to complex vascular problems of the
thoracic aorta. In 1991, Volodos et al16 reported the first
endovascular graft placement into a thoracic aorta. In
1991, Parodi, Palmaz, and Barone17 reported the first
series of abdominal aortic aneurysm repair with stent-
grafting, drawing worldwide attention to the potential of
this technology. A Stanford group reported the first large
clinical series of endovascular stent-grafts of the thoracic
aorta in 1994.18 Since then, many centers have turned
attention to the treatment of thoracic aortic diseases.6-11,19
Endovascular stent-grafting of the descending thoracic
aorta has been reported for a variety of aortic diseases,
including dissection, aneurysms, aortobronchial fistulas,
and penetrating ulcers.7,20-27 Although long-term data
have yet to be published, the advantages of endovascular
stent-grafting over conventional surgical treatment are a
shorter operating time, less blood loss, and shorter hospi-
talization. Conceptually, the strategy offers a more simpli-
fied approach. Operative mortality rates in the largest series
have been reported to be 8.7%.20
Early experience with stent-grafting of the thoracic
aorta used a variety of “first-generation” devices. These
were primarily Gianturco (Cook) or nitinol stents covered
with polytetrafluoroethylene graft material, deployed
through a somewhat large and cumbersome sheath. These
bulky handmade devices were somewhat difficult to deploy
and had a tendency to move with the force of aortic
pulsation. Various methods were used to reduce the force
of systole, but the conventional methods of deployment of
stent-grafts resulted in a “wind sock” movement and im-
peded accurate placement.6,28,29 The result was migra-
tions, endoleaks, and conversions. Previous reports have
attributed a substantial portion of complications and mor-
tality to graft problems arising from the crude constructs of
the first-generation devices. Clearly, limitations in the orig-
inal grafts tempered enthusiasm. Our experience with these
first-generation devices mirrored those of other centers,
and we remained skeptical about the widespread acceptance
of these forms of stent-grafts before the availability of
commercial devices.9,28,29
The Gore Excluder design embodies many sought after
improvements in stent-graft design. An innovative deploy-
ment mechanism solves part of the problem of graft migra-
tion during placement. By rapidly deploying the middle
first, the graft avoids the wind-sock characteristics of the
first-generation devices and is less prone to movement. The
flexibility of the delivery system also allows for positioning
along the curves of the distal aortic arch and distal descend-
ing thoracic aorta without distortion. The device is easily
trackable and is relatively low profile. A trifold balloon is
also an improvement in design and allows for graft apposi-
tion and expansion without the stent-graft migration that is
seen with complete occlusion balloons.
Since February of 2000, we have been using the Gore
Excluder exclusively for thoracic stent-grafting. Our single-
center Investigational Device Exemption differed from the
corporate-sponsored studies by broadening the inclusion
criteria beyond the treatment of nonsurgical patients with
nonruptured descending thoracic aneurysms. We treated
surgical and nonsurgical candidates with aneurysms, dissec-
tions, fistulas, pseudoaneurysms, and traumatic ruptures.
The patients excluded from the study had aortic morphol-
ogy that did not allow for stent-grafting.
We treated both acute and chronic dissections with
endovascular techniques (Fig 7). This necessitated a high
degree of procedural acumen to determine entry points of
dissection and to revascularize malperfused vascular beds.
Determination of the true and false lumens required a
combination of arteriography, IVUS, TEE, and wire tech-
niques. If all vital vascular branches were perfused by the
true lumen, then the graft was placed within the true
lumen, at the site of the intimal tear, excluding false lumen
flow. If, however, vascular beds were perfused by the false
lumen, then we performed a technically complex balloon or
wire fenestration with stent-graft placement to exclude the
false lumen and maintain visceral vessel flow. As with tho-
racic aneurysms that involved the lower third of the tho-
racic aorta, long thoracic dissections required careful iden-
tification of the celiac axis, and these vessels, as opposed to
the left subclavian, became the most important vascular
landmark. Furthermore, in these dissections, the stent-
grafts spanned large portions of the descending thoracic
aorta, covering several intercostal arteries; we had no in-
stances of paraplegia.
Many lesions were located in serpentine areas of the
aorta, such as distal arch lesions, large tortuous aneurysms,
and graft pseudoaneurysms. The stent-graft readily con-
formed to the contours of the aorta because of its flexibility,
another characteristic not shared with the first generation
devices. Only two patients had endoleaks, probably as the
result of aortic curvature, and both endoleaks resolved with
placement of an additional graft.
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We have treated three aortobronchial fistulas with the
Gore Excluder with complete amelioration of hemoptysis
in all patients. Conceptually, the placement of such a graft
is a risk for a secondary infection from a pulmonary or a
primary graft source. However, none of these patients had
signs or symptoms of overwhelming infection or pneumo-
nia, none had pathologic organisms cultured from bron-
chial washings, and none had such symptoms develop after
surgery. No long-term antibiotic was used in any of these
cases. The follow-up period ranged between 6 and 12
months, with a mean of 8 months. Of the five previously
reported cases of aortobronchial fistula stent-grafting, one
patient died in the postoperative period from pneumo-
nia.22-24,27 Therefore, we would hesitate to place a stent-
graft into a grossly infected area. However, the cause of
aortobronchial fistulas is not always infection, and we be-
lieve that stent-graft treatment deserves strong consider-
ation given the reported mortality rate of 25% to 41% with
open repair.30-33
In instances of tortuous, diseased iliac arteries or small-
caliber access vessels, a “bareback” introduction of the
device was used. We theorized that this technique could
have some potential mishaps associated with it. A bareback
introduction of this particular device can cause the device
tip to catch on a plaque, leading to graft damage or a
premature deployment of the graft. Although we are not
aware of such a complication with this device, caution
should be exercised with bareback introduction.
Endovascular stent-grafting for descending thoracic
aortic diseases offers a less invasive alternative to conven-
tional open surgical management. We began using the Gore
Excluder after 2 years of experience with our own hand-
made devices and found it superior. The first-generation
devices exhibited inaccurate deployment and migration
problems that have been virtually eliminated with the Gore
device. Given the relatively low morbidity and mortality
and excellent treatment success rates in our initial experi-
ence, we believe that this device represents an important
improvement in thoracic stent-graft technologies. With the
demonstration of feasibility of thoracic stent-grafting, we
await the long-term report of the durability of this stent-
graft.
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